Global Cancer Immunotherapy Market worth USD 220.32 Billion by 2024

Global Cancer Immunotherapy Market worth USD 220.32 Billion by 2024

Pune, India, April 05, 2019 -- /360iResearch/ -- The report "Global Cancer Immunotherapy Market - Premium Insight, Industry Trends, FPNV Positioning Matrix, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2024 (Q1 2019 Update)", published by 360iResearch, states that the global market was valued at USD 76.52 billion in 2017 and is projected to reach USD 220.32 billion by 2024, growing at a CAGR of 16.31% from 2017 to 2024.

The major forces driving the growth of the cancer immunotherapy market include the growing incidences of cancer and adoption of immunotherapy over other treatment options. Moreover, development of bioinformatic tools enhancing the drug development process rise in healthcare expenditure and healthcare insurance and technological advancement and r&d for the treatment of cancer are also some of the factors that are driving the market growth. However certain factors such as the high cost associated with the treatment may hinder the market growth. In the middle of difficulty lies opportunity such as the clinical trials to cure different cancers in immunotherapy, moving toward personalized immunotherapy, and combination of modern immunotherapy and traditional medicines increasing survival rate. The possible challenges for the market growth is cancer limiting the immune response. But key players in the market are overcoming the challenges with continual improvement and innovation.

Based on function, the global cancer immunotherapy market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer. Based on market, the global cancer immunotherapy market is studied across and Head & Neck Cancer Drugs. Based on product, the global cancer immunotherapy market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. Based on end user, the global cancer immunotherapy market is studied across Cancer Research Institutes, Clinics, and Hospitals. Based on geography, the global cancer immunotherapy market is studied across Americas, Europe, Middle East & Africa, and Asia-Pacific.

The report features a competitive scenario of the cancer immunotherapy market and provides inclusive analysis of key growth strategies adopted by major players. Key company profiled in the study are Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Janssen Global Services, LLC, Merck, Novartis, Pfizer, Seattle Genetics, Inc., and Spectrum Pharmaceuticals, Inc..

About 360iResearch

360iResearch LLP, headquartered in Pune, India, is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as Aerospace & Defense, Agriculture, Automotive & Transportation, Building, Construction & Real Estate, Chemicals & Advanced Material, Consumer Goods & Retail, Energy & Utilities, Food & Beverage, Healthcare & Life Sciences, Information Technology, Packaging, and Semiconductor & Electronics.

Contact:
Miss. Shikha Sachan
Business Lead,
Nyati Elan,
Wagholi, Pune,
Maharashtra,
India - 412207.
USA: +1-530-264-8485
India: +91-9075017818
Email: [email protected]